Fever in immunocompromised hosts

Emergency Medicine Clinics of North America

Volumn 31, Issue 4, 2013, Pages 1059-1071

  Patel, Devang M ^a   Riedel, David J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Emergency department; Fever; Hematopoietic stem cell transplant; HIV; Neutropenic fever; Solid organ transplant; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; ETANERCEPT; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; ITRACONAZOLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CANCER PATIENT; COCCIDIOIDES; COUGHING; FEVER; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRANULOMATOUS INFLAMMATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LATENT TUBERCULOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEUTROPENIA; NIGHT SWEAT; ORGAN TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURGICAL INFECTION; TOXOPLASMOSIS; TUBERCULOSIS; VIRUS INFECTION; WEIGHT REDUCTION;

AIDS; EMERGENCY DEPARTMENT; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANT; HIV; NEUTROPENIC FEVER; SOLID-ORGAN TRANSPLANT; TUMOR NECROSIS FACTOR-Α INHIBITORS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; EMERGENCY SERVICE, HOSPITAL; FEVER; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 84886582850     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.emc.2013.07.002     Document Type: Review

References (50)

1. Mendelson M. Fever in the immunocompromised host. Emerg Med Clin North Am 1998, 16(4):761-779.
2. Pizzo P.A. Fever in immunocompromised patients. NEngl J Med 1999, 341(12):893-900.
3. Buchacz K., Baker R.K., Moorman A.C., et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008, 22(11):1345-1354.
4. Berry S.A., Fleishman J.A., Moore R.D., et al. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. JAcquir Immune Defic Syndr 2012, 59(4):368-375.
5. Stein D.S., Korvick J.A., Vermund S.H. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. JInfect Dis 1992, 165(2):352-363.
6. Moir S., Malaspina A., Ogwaro K.M., et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA 2001, 98(18):10362-10367.
7. Hirschtick R.E., Glassroth J., Jordan M.C., et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. NEngl J Med 1995, 333(13):845-851.
8. Klugman K.P., Madhi S.A., Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007, 20(1):11-15.
9. Kelley C.F., Checkley W., Mannino D.M., et al. Trends in hospitalizations for AIDS-associated Pneumocystis jiroveci pneumonia in the United States (1986 to 2005). Chest 2009, 136(1):190-197.
10. Corbett E.L., Watt C.J., Walker N., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163(9):1009-1021.
11. Janoff E.N., Breiman R.F., Daley C.L., et al. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992, 117(4):314-324.
12. Kales C.P., Murren J.R., Torres R.A., et al. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med 1987, 147(8):1413-1417.
13. Crans C.A., Boiselle P.M. Imaging features of Pneumocystis carinii pneumonia. Crit Rev Diagn Imaging 1999, 40(4):251-284.
14. Barnes P.F., Bloch A.B., Davidson P.T., et al. Tuberculosis in patients with human immunodeficiency virus infection. NEngl J Med 1991, 324(23):1644-1650.
15. Horner R.D., Bennett C.L., Rodriguez D., et al. Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995, 152(5 Pt 1):1435-1442.
16. Wheat L.J., Connolly-Stringfield P.A., Baker R.L., et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine 1990, 69(6):361-374.
17. Ampel N.M., Dols C.L., Galgiani J.N. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993, 94(3):235-240.
18. Park B.J., Wannemuehler K.A., Marston B.J., et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23(4):525-530.
19. Murakawa G.J., Kerschmann R., Berger T. Cutaneous Cryptococcus infection and AIDS: report of 12 cases and review of the literature. Arch Dermatol 1996, 132(5):545-548.
20. Asawavichienjinda T., Sitthi-Amorn C., Tanyanont V. Serum cryptococcal antigen: diagnostic value in the diagnosis of AIDS-related cryptococcal meningitis. JMed Assoc Thai 1999, 82(1):65-71.
21. Porter S.B., Sande M.A. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. NEngl J Med 1992, 327(23):1643-1648.
22. Baumgartner J.E., Rachlin J.R., Beckstead J.H., et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. JNeurosurg 1990, 73(2):206-211.
23. Dieterich D.T., Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. JAcquir Immune Defic Syndr 1991, 4(Suppl 1):S29-S35.
24. Drew W.L., Paya C.V., Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 2001, 1:307-312.
25. Fishman J.A., Issa N.C. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010, 24(2):273-283.
26. Fishman J.A. Infection in solid-organ transplant recipients. NEngl J Med 2007, 357(25):2601-2614.
27. Fishman J.A. Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transpl 2011, 17(Suppl 3):S34-S37.
28. Savitsky E.A., Votey S.R., Mebust D.P., et al. Adescriptive analysis of 290 liver transplant patient visits to an emergency department. Acad Emerg Med 2000, 7(8):898-905.
29. Unterman S., Zimmerman M., Tyo C., et al. Adescriptive analysis of 1251 solid organ transplant visits to the emergency department. West J Emerg Med 2009, 10(1):48-54.
30. Turtay M.G., Oguzturk H., Aydin C., et al. Adescriptive analysis of 188 liver transplant patient visits to an emergency department. Eur Rev Med Pharmacol Sci 2012, 16(Suppl 1):3-7.
31. Fishman J.E., Rabkin J.M. Thoracic radiology in kidney and liver transplantation. JThorac Imaging 2002, 17(2):122-131.
32. Dummer J.S., Thomas L.D. Risk factors and approaches to infections in transplant recipients. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2010, 3821-3837. Elsevier, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
33. Grim S.A., Clark N.M. Management of infectious complications in solid-organ transplant recipients. Clin Pharmacol Ther 2011, 90(2):333-342.
34. Mehrabi A., Fonouni H., Wente M., et al. Wound complications following kidney and liver transplantation. Clin Transplant 2006, 20(Suppl 17):97-110.
35. Zuckermann A., Barten M.J. Surgical wound complications after heart transplantation. Transpl Int 2011, 24(7):627-636.
36. Baden L.R., Bensinger W., Angarone M., et al. Prevention and treatment of cancer-related infections. JNatl Compr Canc Netw 2012, 10(11):1412-1445.
37. Freifeld A.G., Bow E.J., Sepkowitz K.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52(4):e56-e93.
38. Klastersky J., Ameye L., Maertens J., et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007, 30(Suppl 1):S51-S59.
39. Klastersky J., Awada A., Paesmans M., et al. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2011, 78(3):185-194.
40. Bodey G.P., Jadeja L., Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985, 145(9):1621-1629.
41. Paul M., Soares-Weiser K., Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003, 326(7399):1111.
42. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363(22):2091-2101.
43. Wingard J.R., Hsu J., Hiemenz J.W. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010, 24(2):257-272.
44. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009, 44(8):453-455.
45. Koo S., Marty F.M., Baden L.R. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010, 24(2):285-306.
46. Salvana E.M., Salata R.A. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009, 22(2):274-290.
47. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38(9):1261-1265.
48. Centers for Disease Control and Prevention (CDC) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004, 53(30):683-686.
49. Wallis R.S., Broder M., Wong J., et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005, 41(Suppl 3):S194-S198.
50. Domm S., Cinatl J., Mrowietz U. The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008, 159:1217-1228.